Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Pandion Operations Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are currently 2 pending office actions. These actions are handled by 1 distinct examiner across 2 distinct art units, which is a concentration of workload for a single individual across different specialized groups. This alignment suggests that the examiner's expertise is applicable to multiple facets of the company's pharmaceutical technology.
The busiest examiner for the portfolio is MERTZ, PREMA MARIA, who is managing 2 busiest examiner pending actions. This accounts for the total of 2 pending office actions currently active. The involvement of 2 distinct art units suggests that while the technology spans different specialized areas, the prosecution is entirely centralized under the review of the busiest examiner. This centralization allows for a consistent prosecution strategy, as a single individual is responsible for evaluating the claims across different technical classifications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MERTZ, PREMA MARIA | 2 | 71.8% | +34.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18604963 | IL-2 MUTEINS AND USES THEREOF | MERTZ, PREMA MARIA | — |
| 18585285 | IL-2 MUTEINS AND USES THEREOF | MERTZ, PREMA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18604963 | IL-2 MUTEINS AND USES THEREOF | MERTZ, PREMA MARIA | 1674 | §112DP | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18585285 | IL-2 MUTEINS AND USES THEREOF | MERTZ, PREMA MARIA | 1646 | §112DP | Non-Final OA | — | Pending | Feb 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPandion Operations Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 1 examiners.
Prema Maria Mertz has the most, with 2 of Pandion Operations Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
